BioNotebook: Savara, Avanir, Raptor, TetraLogic
This article was originally published in Scrip
Executive Summary
Savara's AeroVanc gets QIDP, fast-track nods; Avanir's AVP-923 fails in Phase II MS pain study; Raptor advances Procysbi for mitochondrial disorders; and TetraLogic resizes IPO.